Bettel
Pro
Re: Старые клячи. Гасконь стр. 721
Катя, насколько я помню, последние исследования показали, что ЦОГ-2 учавствует не только в воспалительных процессах, а каким-то образом вовлечен в сердечно-сосудитую деятельность как минимум, поэтому ингибирование ЦОГ-2 повышает риск сердечных проблем (к счастью, у лошадей не так часто, как у людей). Вот отрывок. Так что не язва, так сердечные проблемы. За все приходится платить
"The recent withdrawal of the human drug, Vioxx® (refecoxib), a systemic COX-2 inhibitor now associated with adverse cardiovascular effects (increased blood pressure, myocardial infarction and thrombotic stroke), is further evidence that more research is needed to understand the mode of action of these drugs and the role the COX enzymes play. Fortunately, equine veterinarians do not encounter cardiovascular disease nearly as frequently as human physicians treating people. The cardiovascular complications in people appear to result from the resence of COX-2 in the cardiovascular system in patients without inflammation. Horses may well have COX-2 in their cardiovascular system just as people do, but ‘heart attacks’ are very rare in horses, making this less of a consideration in equine medicine. It has also been shown that COX-2 is present in the kidney under normal circumstances in both people and animals. Because of the potential for adverse effects on the kidneys, veterinarians must be cautious with COX-2 inhibitors when they become available in the future."
Катя, насколько я помню, последние исследования показали, что ЦОГ-2 учавствует не только в воспалительных процессах, а каким-то образом вовлечен в сердечно-сосудитую деятельность как минимум, поэтому ингибирование ЦОГ-2 повышает риск сердечных проблем (к счастью, у лошадей не так часто, как у людей). Вот отрывок. Так что не язва, так сердечные проблемы. За все приходится платить
"The recent withdrawal of the human drug, Vioxx® (refecoxib), a systemic COX-2 inhibitor now associated with adverse cardiovascular effects (increased blood pressure, myocardial infarction and thrombotic stroke), is further evidence that more research is needed to understand the mode of action of these drugs and the role the COX enzymes play. Fortunately, equine veterinarians do not encounter cardiovascular disease nearly as frequently as human physicians treating people. The cardiovascular complications in people appear to result from the resence of COX-2 in the cardiovascular system in patients without inflammation. Horses may well have COX-2 in their cardiovascular system just as people do, but ‘heart attacks’ are very rare in horses, making this less of a consideration in equine medicine. It has also been shown that COX-2 is present in the kidney under normal circumstances in both people and animals. Because of the potential for adverse effects on the kidneys, veterinarians must be cautious with COX-2 inhibitors when they become available in the future."
)
...
